BANGKOK, April 12, 2025 /PRNewswire/ -- Following the 7.7-magnitude earthquake that struck Myanmar's Mandalay region on March 28, 2025, agri-tech leader FAMSUN launched a swift, cross-border response coordinated through its Southeast Asia hub to support the recovery of the critical animal feed industry. The quake significantly damaged key feed production facilities, halting production at major feed mills operated by partners like CP Group, New Hope, Sunjin, KSP Myanmar, and Diamond.
Within 24 hours, FAMSUN formed an eight-member joint technical expert task force from its Bangkok regional headquarters. Navigating significant travel disruptions with support from regional colleagues, the team reached the Mandalay epicenter by April 5 and immediately began recovery operations.
Restoring Production and Safeguarding Food Supply
In just 48 hours, FAMSUN successfully restored stable operations at four key feed mills in the Mandalay area. One facility saw repair time cut by 60% thanks to the innovative application of pre-fabricated modular components in its damaged conveying system.
These efforts were key to restoring feed supply for Myanmar's livestock sector and supporting the country's food production.
Humanitarian Support for Affected Communities
Beyond technical recovery efforts, FAMSUN also extended critical humanitarian aid to communities impacted by the earthquake. Valued at over 40 million Myanmar Kyat, the aid package included essential supplies such as medicine, food, drinking water, and cash assistance.
Working closely with its partners and clients, FAMSUN delivered these supplies directly to affected families through local feed mill facilities and with the support of organizations including the China Enterprise Chamber of Commerce in Myanmar (CECCM), the Myanmar Sichuan and Chongqing Chamber of Commerce (MSCC), and the Myanmar Livestock Federation (Mandalay).
"FAMSUN's aid during this critical time brings hope for recovery to the people and the industry," stated Dr. Nay Thuyein, Chairman of the Myanmar Livestock Federation (Mandalay).
Regional Cooperation in Action
Benefiting from Thailand's regional logistics strengths, FAMSUN's cross-border relief effort highlighted the role of private-sector expertise in enhancing crisis response capabilities.
"We will continue to deepen local cooperation and contribute our professional expertise to the high-quality development of the region's agro-industry," affirmed Jason Fan, Vice President of FAMSUN. FAMSUN is now extending support to other affected areas like Taunggyi, reaffirming its commitment to Southeast Asia's food security and resilience.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
FAMSUN Team Restores Myanmar's Feed Production After Earthquake
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd. The article, titled "Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up", presents detailed subgroup analysis of infants under six months of age, following the primary results published in The New England Journal of Medicine in September 2024.
RSV: An Urgent Unmet Medical Need
Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in children under six years old. With millions of cases annually worldwide, especially among infants under six months, RSV imposes a significant burden on families and healthcare systems. Current treatments are limited to symptomatic and supportive care, with no approved direct-acting antiviral therapies available.
Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's efficacy in hospitalized infants ≤6 months, and demonstrating long-term benefits in reducing recurrent wheezing and asthma.
Study Design
This multicenter, randomized, double-blind, placebo-controlled Phase III trial was conducted at 30 sites in 28 hospitals across China. The trial included two parts:
Infants were randomized in a 2:1 ratio to receive ziresovir or placebo for five days, with a 24-month follow-up. The latest publication focuses on infants aged six months or younger.
Key Findings
1. Significant Efficacy
2. Long-Term Safety and Respiratory Health Benefits
These long-term benefits suggest early antiviral intervention may reduce the risk of chronic respiratory conditions.
A New Era in RSV Treatment
Unlike existing RSV treatments focused solely on symptom relief, ziresovir is the first RSV-targeted antiviral therapy with demonstrated clinical efficacy in infants under six months—those most at risk of severe complications. These findings introduce a new therapeutic paradigm for RSV treatment and prevention of long-term sequelae.
The results were presented by Dr. Jim Wu, CEO of ArkBio, at the 13th International RSV Symposium in Brazil, receiving recognition from the global RSV research community.
Prof. Xin Ni, principal investigator of the Airflo study and professor at Beijing Children's Hospital, Capital Medical University, commented:
"This pivotal Phase III trial provides the first solid evidence of an effective antiviral treatment for RSV in high-risk infants. Following our initial publication in The New England Journal of Medicine, this deeper analysis in infants under six months published in The Lancet Child & Adolescent Health further validates ziresovir's safety, efficacy, and long-term benefit. We are proud of our team's commitment and look forward to bringing this drug to patients in China and worldwide."
For public readers, the article can be accessed at the following link:
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00067-7/fulltext
About Ziresovir
Ziresovir is a first-in-class, oral small-molecule inhibitor targeting the RSV fusion (F) protein. It prevents viral entry and cell-to-cell transmission by blocking syncytia formation, a hallmark of RSV infection. It is the first oral RSV antiviral to successfully complete a pivotal Phase III trial with positive results and has been granted Breakthrough Therapy Designation by the National Medical Products Administration (NMPA) of China.
About ArkBio
ArkBio is a global biotech company focused on developing innovative therapies for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house research and collaborations. Key assets include ziresovir, the first direct-acting RSV antiviral with positive pivotal phase III results globally, and AK0901, an FDA-approved pediatric ADHD therapy with commercialization rights in Greater China.
ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology, Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture investment institutions.
For more information about the company, please visit our website: www.arkbiosciences.com
Investor Inquiries: IR@arkbiosciences.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
